MeiraGTx Holdings plc
MGTX
Rank in Stocks
#9098
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company,... MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Share Price
$9.49
Last synced: 2026-11-09
Market Cap
$911.45M
Change (1 day)
5.44%
Change (1 year)
6.63%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MeiraGTx Holdings plc (MGTX)
Category
Healthcare
Operating Margin for MeiraGTx Holdings plc (MGTX)
Operating Margin as of November 2026 TTM: 46.30%
According to MeiraGTx Holdings plc's latest financial reports, its current operating margin (TTM) is 46.30%. At the end of 2025 the company had an operating margin of -130.20%.
Operating Margin history for MeiraGTx Holdings plc from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 46.30% | -135.56% |
| 2025 | -130.20% | -73.61% |
| 2024 | -493.44% | -49.54% |
| 2023 | -977.82% | 33.79% |
| 2022 | -730.87% | 278.71% |
| 2021 | -192.99% | -51.99% |
| 2020 | -401.94% | -8.31% |
| 2019 | -438.37% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.17% |
US
|
|
| -149.01% | -103.22% |
US
|
|
| 25.57% | -99.45% |
AU
|
|
| 31.23% | -99.33% |
BE
|
|
| 29.35% | -99.37% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about MeiraGTx Holdings plc's operating margin
What is MeiraGTx Holdings plc's operating margin?
MeiraGTx Holdings plc's operating margin is 46.30%, as of Nov 2026.
What was MeiraGTx Holdings plc's operating margin in 2025?
In 2025, MeiraGTx Holdings plc's operating margin was -130.20%, compared with -493.44% in 2024.
How has MeiraGTx Holdings plc's operating margin changed since 2020?
From 2020 to 2025, MeiraGTx Holdings plc's operating margin was highest in 2025 (-130.20%) and lowest in 2023 (-977.82%).
How does MeiraGTx Holdings plc's operating margin compare with similar companies?
MeiraGTx Holdings plc's operating margin (46.30%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.